- Home
- INBS vs KPRX Comparison
INBS vs KPRX Comparison
Compare INBS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- KPRX
- Stock Information
- Founded
- INBS 2016
- KPRX 1998
- Country
- INBS United States
- KPRX United States
- Employees
- INBS N/A
- KPRX N/A
- Industry
- INBS Medical Specialities
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- INBS Health Care
- KPRX Health Care
- Exchange
- INBS Nasdaq
- KPRX Nasdaq
- Market Cap
- INBS 8.7M
- KPRX 9.1M
- IPO Year
- INBS N/A
- KPRX N/A
- Fundamental
- Price
- INBS $1.83
- KPRX $2.86
- Analyst Decision
- INBS
- KPRX Strong Buy
- Analyst Count
- INBS 0
- KPRX 1
- Target Price
- INBS N/A
- KPRX $10.00
- AVG Volume (30 Days)
- INBS 159.7K
- KPRX 1.4M
- Earning Date
- INBS 05-13-2025
- KPRX 08-08-2025
- Dividend Yield
- INBS N/A
- KPRX N/A
- EPS Growth
- INBS N/A
- KPRX N/A
- EPS
- INBS N/A
- KPRX N/A
- Revenue
- INBS $2,936,472.00
- KPRX $20,000.00
- Revenue This Year
- INBS $280.88
- KPRX N/A
- Revenue Next Year
- INBS $126.26
- KPRX N/A
- P/E Ratio
- INBS N/A
- KPRX N/A
- Revenue Growth
- INBS 3.87
- KPRX N/A
- 52 Week Low
- INBS $1.00
- KPRX $2.51
- 52 Week High
- INBS $3.00
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- INBS 58.01
- KPRX 42.65
- Support Level
- INBS $1.52
- KPRX $2.68
- Resistance Level
- INBS $1.73
- KPRX $3.22
- Average True Range (ATR)
- INBS 0.14
- KPRX 0.18
- MACD
- INBS -0.02
- KPRX -0.03
- Stochastic Oscillator
- INBS 68.89
- KPRX 33.21
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.